news
LixiLan-O and LixiLan-L meet primary endpoints
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
List view / Grid view
Sanofi
news
Dupilumab + TCS superior to TCS alone in treating atopic dermatitis
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
news
AbbVie tops the RepTrak ranking for most reputable pharma company in the UK
31 May 2016 | By Victoria White, Digital Content Producer
Reputation Institute has announced that AbbVie, Sanofi and Novo Nordisk top the RepTrak ranking of the most reputable pharmaceutical companies in the UK...
news
EMDAC recommends NDA approval for Sanofi’s type 2 diabetes treatment
26 May 2016 | By Victoria White, Digital Content Producer
The FDA's EMDAC has recommended the approval of the NDA for the fixed-ratio combination of insulin glargine and lixisenatide...
news
Sanofi files consent solicitation to replace Medivation’s Board
25 May 2016 | By Victoria White, Digital Content Producer
Sanofi says it had 'no choice' but to commence a process to elect eight independent directors who are more open to evaluating Sanofi's takeover proposal...
news
NICE recommends alirocumab and evolocumab in draft guidance
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
article
Mass Spectrometry: In-Depth Focus 2016
In this Mass Spectrometry In-Depth Focus: Novel trends in glycosylation analysis of biotherapeutics by mass spectrometry; The use of mass spectrometry for the characterisation of proteins in small molecule drug discovery; Mass Spectrometry Q&A...
news
Medivation’s Board rejects Sanofi’s unsolicited proposal
3 May 2016 | By Victoria White, Digital Content Producer
Medivation’s Board has determined that the proposal from Sanofi to acquire Medivation for $52.50 per share substantially undervalues the company...
news
3rd Pharmaceutical Traceability Forum to attract expert serialization and packaging professionals from across the nation
29 April 2016 | By 3rd Pharmaceutical Traceability Forum
Harmonize serialization plans to achieve compliance. Supply chain stakeholders must take a comprehensive view of their traceability strategy...
news
Sanofi makes $9.3b offer to acquire Medivation
28 April 2016 | By Victoria White, Digital Content Producer
Sanofi has made an unsolicited $9.3 billion offer to acquire Medivation, the maker of prostate cancer drug Xtandi...
news
Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
news
World’s first public dengue immunisation programme starts
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
news
Positive topline results from two Phase III dupilumab studies
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
news
Positive results for Praluent in patients undergoing LDL apheresis therapy
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
news
Amgen wins drug patent case against Sanofi and Regeneron
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
